AIM: A confirmed wild-type RAS tumor status is commonly required for prescribing anti-EGFR treatment for metastatic colorectal cancer. This noninterventional, observational research project estimated RAS mutation prevalence from real-world sources. MATERIALS & METHODS: Aggregate RAS mutation data were collected from 12 sources in three regions. Each source was analyzed separately; pooled prevalence estimates were then derived from meta-analyses. RESULTS: The pooled RAS mutation prevalence from 4431 tumor samples tested for RAS mutation status was estimated to be 43.6% (95% CI: 38.8-48.5%); ranging from 33.7% (95% CI: 28.4-39.3%) to 54.1% (95% CI: 51.7-56.5%) between sources. CONCLUSION: The RAS mutation prevalence estimates varied among sources. The reasons for this are not clear and highlight the need for further research.

Adelphi Research Manchester UK

Amgen GmbH Vienna Austria

Amgen Hellas EPE Athens Greece

Amgen Inc Thousand Oaks CA USA

Amgen Kft Budapest Hungary

Amgen Ltd Uxbridge UK

Amgen s r o Prague Czech Republic

Biomarker Solutions London UK

Bioptická laboratoř Plzeň Czech Republic

Centrum Onkologii Instytut im Marii Sklodowskiej Curie Warsaw Poland

Gastrointestinal Cancer Study Group Heraklion Crete Greece

Hellenic Cooperative Oncology Group University of Athens Athens Greece

Masaryk Memorial Cancer Institute Brno Czech Republic

National Cancer Institute Cairo University Cairo Egypt

National Institute of Oncology Budapest Hungary

Oncogene Diagnostics Sp z o o Krakow Poland

Radboud University Medical Center Nijmegen The Netherlands

Semmelweis Medical University Budapest Hungary

Tecnofarma Santiago Chile

University Hospital Frankfurt Germany

University Hospital Hradec Kralove Hradec Kralove Czech Republic

Zobrazit více v PubMed

Torre LA, Siegel RL, Ward EM, Jemal A. Global cancer incidence and mortality rates and trends-an update. Cancer Epidemiol. Biomarkers Prev. 2016;25:16–27. PubMed

Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer. 2015;136:E359–E386. PubMed

van Cutsem E, Cervantes A, Nordlinger B, Arnold D ESMO Guidelines Working Group. Collaborators (20) Ann. Oncol. 2014;25(Suppl. 3):iii1–iii9. PubMed

Tay RY, Wong R, Hawkes EA. Treatment of metastatic colorectal cancer: focus on panitumumab. Cancer Manag. Res. 2015;7:189–198. PubMed PMC

Moorcraft SY, Smyth EC, Cunningham D. The role of personalized medicine in metastatic colorectal cancer: an evolving landscape. Therap. Adv. Gastroenterol. 2013;6:381–395. PubMed PMC

Douillard JY, Oliner KS, Siena S, et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N. Engl. J. Med. 2013;369:1023–1034. PubMed

Schwartzberg LS, Rivera F, Karthaus M, et al. PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer. J. Clin. Oncol. 2014;32:2240–2247. PubMed

Heinemann V, von Weikersthal LF, Decker T, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014;15:1065–1075. PubMed

Seymour MT, Brown SR, Middleton G, et al. Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial. Lancet Oncol. 2013;14:749–759. PubMed PMC

Peeters M, Douillard JY, van Cutsem E, et al. Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: assessment as prognostic and predictive biomarkers of response to panitumumab. J. Clin. Oncol. 2013;31:759–765. PubMed

Peeters M, Kafatos G, Taylor A, et al. Prevalence of RAS mutations and individual variation patterns among patients with metastatic colorectal cancer: a pooled analysis of randomised controlled trials. Eur. J. Cancer. 2015;51:1704–1713. PubMed

Boleij A, Tack V, Taylor A, et al. RAS testing practices and RAS mutation prevalence amongst mCRC patients: results from a Europe-wide survey of pathology centres. BMC Cancer. 2016;16:825. In Press. PubMed PMC

Peeters M, Oliner KS, Parker A, et al. Massively parallel tumor multigene sequencing to evaluate response to panitumumab in a randomized phase III study of metastatic colorectal cancer. Clin. Cancer Res. 2013;19:1902–1912. PubMed

Sorich MJ, Wiese MD, Rowland A, et al. Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials. Ann. Oncol. 2015;26:13–21. PubMed

Boleij A, Tops BB, Rombout PD, et al. RAS testing in metastatic colorectal cancer: excellent reproducibility amongst 17 Dutch pathology centers. Oncotarget. 2015;6:15681–15689. PubMed PMC

Wong NA, Gonzalez D, Salto-Tellez M, et al. RAS testing of colorectal carcinoma – a guidance document from the Association of Clinical Pathologists Molecular Pathology and Diagnostics Group. J. Clin. Pathol. 2014;67:751–757. PubMed

Malapelle U, Carlomagno C, de Luca C, et al. KRAS testing in metastatic colorectal carcinoma: challenges, controversies, breakthroughs and beyond. J. Clin. Pathol. 2014;67:1–9. PubMed

van Krieken JH, Jung A, Kirchner T, et al. KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program. Virchows Arch. 2008;453:417–431. PubMed

Tack V, Ligtenberg MJ, Tembuyser L, et al. External quality assessment unravels interlaboratory differences in quality of RAS testing for anti-EGFR therapy in colorectal cancer. Oncologist. 2015;20:257–262. PubMed PMC

Li Y, Fu XH, Yuan JQ, et al. Colorectal cancer: using blood samples and tumor tissue to detect K-ras mutations. Expert Rev. Anticancer Ther. 2015;15:715–725. PubMed